Value Line - An Iconic, Debt-Free, Name Near a Decade Low

Value Line [NDQ:VALU - $22.89] provides investment advisory services to mutual funds, institutions and individual clients, and publishes investment-related periodicals. The Value Line Publishing subsidiary publishes investment advisories that rate and evaluate common stocks, options, mutual funds, and convertibles. Value Line also produces investment-related software and manages a family of mutual funds, pension funds, institutional and individual portfolios through Value Line Asset Management.
The company’s investment advice can be found in almost any good-sized library in America as well as on the shelves of almost every American brokerage firm. The company recently paid a $47,706,000 fine to settle with the SEC regarding a variety of mutual fund practices that were not related to their core business of providing investment related information. Jean Bernhard Buttner resigned as CEO and Chairman over this issue last November and was replaced by Howard Brecher, Value Line’s Chief Legal Officer, who became the Acting Chairman.
The fiscal third quarter showed decent results with earnings (excluding the SEC settlement) of $0.36 per share versus a $0.27 estimate and year earlier EPS of $0.38. The lone analyst covering Value Line stock now carries FY 2010 (ends April 30, 2010) and FY 2011 estimates of $1.45 and $1.52 excluding the one-time charge.
Even after paying the large SEC fine Value Line remains debt-free and holds about $14 million in treasury cash. The dividend had been $0.40 quarterly through January 2009 but was cut to $0.30 in April last year and to $0.20 quarterly last July when the need to conserve cash for the settlement became defined. I think the attractive current yield of 3.5% is now sustainable.
Here are the per share, fully diluted, numbers from continuing operations for the FYs 2005 – 2009 as reported by Morningstar:
|
FY* |
Sales |
EPS |
Dividends |
52- Week Range**
|
P/E Range |
|
2005 |
84.50 |
2.10 |
1.00 |
$33.36 – $43.37 |
15.9x – 20.7x |
|
2006 |
85.20 |
2.40 |
1.00 |
$33.11 – $57.70 |
13.8x – 24.0x |
|
2007 |
83.60 |
2.50 |
1.15 |
$39.14 – $56.00 |
15.7x – 22.4x |
|
2008 |
82.70 |
2.60 |
1.20 |
$24.51 - $47.20 |
9.4x – 18.2x |
|
2009 |
69.20 |
2.30 |
1.50 |
$20.65 - $39.98 |
9.0x – 17.4x |
|
* FYs end April 30 of the same year **Calendar year High/Lows |
|||||
Clearly, Value Line has ‘earnings power’ of at least $2 per share in normal times. Excepting the November 2008 – March 9, 2009 meltdown period Value Line has almost never traded below about 15x earnings. Now that the SEC matter is behind the company and with new upper management in place I think Value Line can get back to much better earnings and a $30 – $40 share price again. Is that a reasonable target? Value Line shares hit peak prices of between $39.98 and $57.70 during each of the past five years. They touched $36.52 as recently as last summer.
With a clean balance sheet, a higher-than-CD-rate yield and a well entrenched market position, there appears to be little risk of a serious decline from today’s closing price of $22.89. VALU touched a new 52-week low during today’s trading, getting me interested in taking a position.
Of the 10 million outstanding shares about 87% are held by insiders with 9% of the rest held by mutual funds.
Some well-regarded holders (as of Dec. 31, 2009) included:
……………………………………………………… # shares ………… % Out.
Dimensional Fund Advisors …………… 201,841 …………. 2.02%
Wellington Management ………..……. 184,884 …….…… 1.85%
American Century Companies ………. 125,700 …………. 1.26%
Northern Trust Corp. …………………….. 50,558 …………… 0.51%
Oppenheimer Funds ……………………… 47,279 …………… 0.47%
Royce and Associates ……………………. 35,487 …………… 0.36%
BlackRock Institutional Trust Co .…… 33,001 …………… 0.33%
BlackRock Fund Advisors ………..…….. 28,824 ………….. 0.29%
State Street Corp. ……………………..….. 23,787 ………….. 0.24%
These shares are very thinly traded. If you plan to buy, use limit orders and be patient. Average trading volume is low and the bid/ask spreads vary from not too large to fairly wide depending on the market mood.
While nobody can predict a sale of the whole company the heavy and highly concentrated insider holdings could facilitate a deal if the founding family ever decides to unload the business. There are a few well-matched potential acquirers if the Bernhard family wants to exit the business.
Dr. Paul Price
Disclosure: Author bought shares of Value Line in today’s trading session.
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

